SCHEMBL2460161

SCHEMBL2460161

CC(C)c1[nH]c2nc(N)nn2c(=O)c1Cc1cccc(Cl)c1

nearest known ligand 0.53

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
CCR2 P41597 16/20 0.53
CCR5 P51681 5/20 0.53
PDE5A O76074 1/20 0.46
PDE9A O76083 1/20 0.46
PDE1A P54750 1/20 0.46
PDE1B Q01064 1/20 0.46
PDE1C Q14123 1/20 0.46
ALKBH3 Q96Q83 1/20 0.41
ADCY10 Q96PN6 1/20 0.41
PNP P00491 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2459259 0.86 CCR2 (0.51) CCR2CCR5ALKBH3ADCY10PNP
SCHEMBL2465055 0.84 CCR2 (0.50) CCR2CCR5ALKBH3ADCY10PNP
SCHEMBL2459960 0.84 CCR2 (0.46) CCR2CCR5PDE5APDE9APDE1A
SCHEMBL2456143 0.82 CCR2 (0.52) CCR2CCR5ALKBH3ADCY10PNP
SCHEMBL2460787 0.82 CCR2 (0.44) CCR2CCR5ALKBH3ADCY10PNP
SCHEMBL2462646 0.82 CCR2 (0.45) CCR2CCR5ALKBH3ADCY10PNP
SCHEMBL2461260 0.81 CCR2 (0.48) CCR2CCR5PDE5APDE9APDE1A
SCHEMBL2458554 0.81 CCR2 (0.53) CCR2CCR5ALKBH3ADCY10
SCHEMBL2456001 0.80 CCR2 (0.52) CCR2CCR5
SCHEMBL2463316 0.75 THRB (0.46) CCR2ALKBH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011114148-A1 4H- [1, 2, 4] TRIAZOLO [5, 1 -B] PYRIMIDIN-7 -ONE DERIVATIVES AS CCR2B RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2011-09-22 WO claimed
WO-2011114148-A1 4H- [1, 2, 4] TRIAZOLO [5, 1 -B] PYRIMIDIN-7 -ONE DERIVATIVES AS CCR2B RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2011-09-22 WO disclosed
WO-2011114148-A1 4H- [1, 2, 4] TRIAZOLO [5, 1 -B] PYRIMIDIN-7 -ONE DERIVATIVES AS CCR2B RECEPTOR ANTAGONISTS ASTRAZENECA AB (SE) 2011-09-22 WO disclosed